Christopher O’Brien

机构：Brantford Energy (Canada), Neurocrine Biosciences (United States)

发表论文 53 篇 · 总被引 2463 次 · h-index 25

代表论文

• KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia (2017 · American Journal of Psychiatry · 被引 395)
• Updated practice guideline for dual-energy X-ray absorptiometry (DXA) (2024 · European Journal of Nuclear Medicine and Molecular Imaging · 被引 118)
• The Effects of Valbenazine in Participants with Tardive Dyskinesia (2017 · The Journal of Clinical Psychiatry · 被引 87)
• Osteoporotic Fractures: Diagnosis, Evaluation, and Significance From the International Working Group on DXA Best Practices (2024 · Mayo Clinic Proceedings · 被引 82)
• Differences in Dihydrotetrabenazine Isomer Concentrations Following Administration of Tetrabenazine and Valbenazine (2017 · Drugs in R&D · 被引 35)
• A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia (2019 · Journal of Clinical Psychopharmacology · 被引 33)